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ABSTRACT
The calpains are a family of intracellular cysteine proteases that function in a 
variety of important cellular functions, including cell signalling, motility, apoptosis 
and survival. In early invasive breast cancer expression of calpain-1, calpain-2 
and their inhibitor, calpastatin, have been associated with clinical outcome and 
clinicopathological factors.
The expression of calpain-1, calpain-2 and calpastatin was determined using 
immunohistochemistry on core biopsy samples, in a cohort of large but operable 
inflammatory and non-inflammatory primary breast cancer patients treated with 
neoadjuvant chemotherapy. Information on treatment and prognostic variables 
together with long-term clinical follow-up was available for these patients. Diagnostic 
pre-chemotherapy core biopsy samples and surgically excised specimens were 
available for analysis.
Expression of calpastatin, calpain-1 or calpain-2 in the core biopsies was not 
associated with breast cancer specific survival in the total patient cohort; however, 
in patients with non-inflammatory breast cancer, high calpastatin expression was 
significantly associated with adverse breast cancer-specific survival (P=0.035), as 
was low calpain-2 expression (P=0.031). Low calpastatin expression was significantly 
associated with adverse breast cancer-specific survival of the inflammatory breast 
cancer patients (P=0.020), as was low calpain-1 expression (P=0.003).
In conclusion, high calpain-2 and low calpastatin expression is associated with 
improved breast cancer-specific survival in non-inflammatory large but operable 
primary breast cancer treated with neoadjuvant chemotherapy. In inflammatory 
cases, high calpain-1 and high calpastatin expression is associated with improved 
breast cancer-specific survival. Determining the expression of these proteins may 
be of clinical relevance. Further validation, in multi-centre cohorts of breast cancer 
patients treated with neoadjuvant chemotherapy, is warranted.
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INTRODUCTION
The calpain system is a family of calcium-
activated cysteine proteases including the archetypal 
members’ calpain-1 and calpain-2, and their endogenous 
inhibitor calpastatin. Aberrant expression and activity 
has been described in numerous disease states, including 
Alzheimer’s disease and cancer (reviewed in [1, 2]). 
These proteases function in numerous cellular activities, 
such as cytoskeletal remodelling, cellular signalling, 
survival and apoptosis (reviewed in [1]). The expression 
levels of calpain and calpastatin have been described 
in a number of tumour types, including pancreatic, 
ovarian and gastro-oesophageal [3–5]. In breast cancer, 
high calpain-2 expression is associated with adverse 
breast cancer-specific survival of patients with basal-
like phenotype or triple receptor negative tumours [6]; 
high calpain-1 expression is associated with relapse-free 
survival of HER2 positive patients treated with adjuvant 
chemotherapy followed by trastuzumab [7]; and low 
calpastatin expression is associated with the presence of 
lymphovascular invasion [8]. In breast cancer, high calpain 
expression has been linked with poor prognosis which is 
thought to be due to elevated calpain activity promoting 
cellular survival and cytoskeletal remodelling, which in 
turn, can promote a more invasive phenotype. However, 
the roles for calpain are paradoxical, with studies showing 
its importance in regulation of both apoptosis and survival.
There are varying levels of evidence to suggest a 
role for altered calpain activity in regulating apoptosis 
in response to a variety of chemotherapy agents. Calpain 
can cleave autophagy related gene (Atg) 5, which is 
involved in the formation of autophagosomes. Evidence 
suggests that Atg5 cleaved by calpain is an important pro-
apoptotic event in drug-induced apoptosis [9]. Calpain-1 
and calpain-2 are both activated in vitro after 24 hours 
of paclitaxel treatment of non-small cell lung carcinoma 
cells and are responsible for some of the protease-
mediated processing that occurs in paclitaxel-mediated 
cell death [10]. Furthermore, calpain can cleave Bax, 
a protein that translocates to the mitochondria upon 
induction of apoptosis, in promyelocytic leukaemia cells 
during drug induced apoptosis [11, 12]. In addition to 
altering apoptotic pathways in cancer cells, calpain has 
also been implicated in some of the toxicities associated 
with chemotherapy. Calpain activity has been implicated 
in cardiac injuries following doxorubicin treatment, both 
in-vitro and in-vivo [13, 14], however over-expression of 
calpastatin has also been shown to enhance doxorubicin-
induced cardiac injuries through calpain inhibition [15]. 
In addition, calpain has been shown to degrade neuronal 
calcium sensor 1 (NCS-1) following paclitaxel treatment 
which is important in irreversible peripheral neuropathy 
[16]. Contradictory evidence suggests that calpain activity 
may play a role in survival following drug-induced stress. 
Calpain can proteolyse Myc to generate a transcriptionally 
inactive product that can delay colon cancer cell death 
following treatment with chemotherapy agents [17]. Much 
of the research describes the effects of calpain activation 
in different cancer cell types, and after various drug 
treatments. The perplexing nature of calpain proteolysis 
suggests important roles in numerous cellular activities 
that are dependent upon cellular context.
The aim of this study was to investigate the 
expression of calpain-1, calpain-2 and calpastatin in 
diagnostic, core biopsy specimens from women with large 
but operable primary breast cancer who were subsequently 
treated with neoadjuvant chemotherapy prior to surgical 
excision of residual tumour. Where matched surgically 
excised specimens were available, calpain-1, calpain-2 
and calpastatin expression was also determined in these 
samples. Data was analysed against pathological response, 
patient survival and available clinicopathological data to 
determine the effect of this protease system on disease 
outcome.
RESULTS
Calpain system expression
Calpain-1, calpain-2 and calpastatin expression 
displayed heterogenic cytoplasmic staining which varied 
from weak to strong with representative staining shown 
in Figure 1. Antibody specificity was demonstrated using 
Western blotting. Some cases were not assessed due to 
missing sample or insufficient representative tumour. 
Calpastatin had a median H-score of 140, ranging from 
10-240 in the core biopsy samples, and 175, ranging from 
103-250 in the surgically resected samples. Calpain-1 
had a median H-score of 140, ranging from 0-240 in the 
core biopsy samples, and 150, ranging from 0-240 in 
the surgically resected samples. Calpain-2 had a median 
H-score of 160, ranging from 0-235 in the core biopsy 
samples, and 147.5, ranging from 0-183 in the surgically 
resected samples.
Spearman’s rank order correlation test 
demonstrated no correlation for calpastatin (r2=0.155, 
P=0.253), calpain-1 (r2=0.178, P=0.193) or calpain-2 
expression (r2=-0.075, P=0.561) in the core biopsy or the 
surgically excised specimen. Comparisons were made 
between core-biopsy and surgically excised specimens 
in non-inflammatory or inflammatory subgroups. In 
the non-inflammatory subgroup no correlation for 
calpastatin (r2=0.238, P=0.130), calpain-1 (r2=0.068, 
P=0.682) or calpain-2 expression (r2=-0.236, P=0.119) 
in the core biopsy or the surgically excised specimen 
was observed. In the inflammatory subgroup no 
correlation for calpastatin (r2=0.077, P=0.811), or 
calpain-2 expression (r2=-0.204, P=0.464) in the core 
biopsy or the surgically excised specimen was observed. 
Calpain-1 expression in the core biopsy or the surgically 
excised specimen was significantly correlated in the 
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inflammatory subgroup (r2=0.680, P=0.011), although 
the correlation coefficient suggests this is of marginal 
biological relevance.
In the core biopsy samples, calpain-1 expression 
was correlated with calpastatin expression (r2=0.283, 
P=0.001); however, the correlation coefficient suggests 
this is of marginal biological relevance. Calpain-1 
expression was not correlated with calpain-2 expression 
(r2=-0.004, P=0.965); calpain-2 expression was not 
correlated with calpastatin expression (r2=0.097, P=0.258). 
In the surgically excised specimens no correlations were 
observed in any of the pairwise comparisons of protein 
expression.
Relationship between calpain system expression 
and clinicopathological variables
The expression of calpain-2 in the core biopsies was 
not associated with any clinicopathological variables that 
were determined at the time the core biopsy was taken 
(Table 1). High expression of calpastatin was associated 
with ER positive tumours (χ2=5.720, d.f.=1, P=0.017) 
and high calpain-1 expression was associated with PgR 
positive tumours (χ2=5.457, d.f.=1, P=0.019).
The expression of calpastatin and calpain-1 in the 
surgically excised samples was not associated with any 
clinicopathological variables determined on the surgically 
excised sample (Table 2). High calpain-2 expression was 
associated with inflammatory disease (χ2=6.792, d.f.=1, 
P=0.009) (Table 2). No association was observed between 
calpain or calpastatin expression and lymphovascular 
invasion when assessed in haematoxylin and eosin stained 
surgically resected specimens.
Calpain system expression and patient survival
When plotted according to the Kaplan-Meier 
method with significance determined using the log-
rank test, the expression of calpastatin, calpain-1 and 
calpain-2 in the core biopsies was not associated with 
breast cancer specific survival in the total patient cohort 
(P=0.470, P=0.790, P=0.174 respectively). Expression 
was separately analysed in both the non-inflammatory 
cases and inflammatory breast cancer, with the latter 
Figure 1: Representative photomicrographs following immunohistochemical staining of A. low calpastatin, B. high 
calpastatin, C. low calpain-1, D. high calpain-1, E. low calpain-2 and F. high calpain-2 staining. Photomicrographs are shown at 100× 
magnification with 200× magnification inset box where scale bar shows 100μm.
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Table 1: Associations between the expression of calpastatin, calpain-1 and calpain-2 determined in core biopsy 
samples with clinicopathological variables also determined from the core biopsy samples 
Calpastatin Calpain-1 Calpain-2
Low High P value Low High P value Low High P value
Lymph node status
 Negative 26 (28.6%)
18 
(19.8%)
0.442
30 
(35.3%)
12 
(14.1%)
0.867
30 
(33.0%)
15 
(16.5%)
0.565
 Positive 24 (26.4%)
23 
(25.3%)
30 
(35.3%)
13 
(15.3%)
28 
(30.8%)
18 
(19.8%)
Pathological 
response
 None/minimal 10 (6.6%)
2  
(1.7%)
0.081
7 (6.4%) 2 (1.8%)
0.250
6 (5.1%) 6 (5.1%)
0.593 Partial 43 (37.1%)
43 
(37.1%)
53 
(48.6%)
29 
(26.6%)
56 
(47.9%)
31 
(26.5%)
 Complete 11 (9.5%) 7 (6.0%)
15 
(13.8%) 3 (2.8%)
12 
(10.3%) 6 (5.1%)
Inflammatory 
disease
 Non-inflammatory
49 
(36.6%)
43 
(32.1%)
0.350
58 
(46.4%)
28 
(22.4%)
0.932
64 
(47.4%)
30 
(22.2%)
0.109
 Inflammatory
26 
(19.4%)
16 
(11.9%)
26 
(20.8%)
13 
(10.4%)
22 
(16.3%)
19 
(14.1%)
Tumour grade
 1 3 (2.6%) 3 (2.6%)
0.825
5 (4.6%) 1 (0.9%)
0.596
3 (2.6%) 3 (2.6%)
0.365 2
29 
(25.2%)
21 
(18.3%)
29 
(26.6%)
14 
(12.8%)
27 
(23.3%)
22 
(19.0%)
 3 31 (27.0%)
28 
(24.3%)
38 
(34.9%)
37 
(33.9%)
41 
(35.3%)
20 
(17.2%)
ER status
 Negative 36 (26.9%)
17 
(12.7%)
0.017
38 
(30.4%)
13 
(10.4%)
0.111
35 
(25.9%)
19 
(14.1%)
0.716
 Positive 38 (28.4%)
43 
(32.1%)
45 
(36.0%)
29 
(23.2%)
50 
(37.0%)
31 
(23.0%)
PgR status
 Negative 40 (29.9%)
27 
(20.1%)
0.297
48 
(38.4%)
15 
(12.0%)
0.019
46 
(34.1%)
23 
(17.0%)
0.362
 Positive 34 (25.4%)
33 
(24.6%)
35 
(28.0%)
27 
(21.6%)
39 
(28.9%)
27 
(20.0%)
HER2 status
 Negative 39 (41.9%)
33 
(35.5%)
0.885
50 
(57.5%)
20 
(23.0%)
0.587
45 
(48.4%)
26 
(28.0%)
0.717
 Positive 11 (11.8%)
10 
(10.8%)
11 
(12.6%) 6 (6.9%)
13 
(14.0%) 9 (9.7%)
The P values are resultant from Pearson χ2 test of association or Fishers Exact when an asterisk is included. Significant P 
values are indicated in bold. ER is oestrogen receptor and PgR is progesterone receptor.
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Table 2: Associations between the expression of calpastatin, calpain-1 and calpain-2 determined in surgically excised 
samples with clinicopathological variables also determined from the surgically excised samples 
Calpastatin Calpain-1 Calpain-2
Low High P value Low High P value Low High P value
Lymph node status
 Negative 17 (37.0%)
2 
(4.3%)
0.086*
11 
(22.9%)
8 
(16.7%)
0.675
12 
(25.5%)
6 
(12.8%)
0.869
 Positive 17 (37.0%)
10 
(21.7%)
15 
(31.3%)
14 
(29.2%)
20 
(42.6%)
9 
(19.1%)
Pathological 
response
 None/minimal 8  (15.1%)
1 
(1.9%)
0.418*
6 
(10.2%) 4 (6.8%)
0.506*
8  
(14.0%) 2 (3.5%)
0.295*
 Partial 30 (56.6%)
14 
(26.4%)
23 
(39.0%0
26 
(44.1%)
28 
(49.1%)
19 
(33.3%)
Inflammatory 
disease
 Non-inflammatory
31 
(56.4%)
12 
(21.8%)
0.730*
25 
(41.0%)
21 
(34.4%)
0.334
32 
(53.3%)
13 
(21.7%)
0.009
 Inflammatory 8 (14.5%) 4 (7.3%) 6 (9.8%)
9 
(14.8%) 5 (8.3%)
10 
(16.7%)
Tumour grade
 1 3 (6.0%) 1 (2.0%)
0.774
1 (1.9%) 3 (5.8%)
0.227
2 (3.8%) 2 (3.8%)
0.841 2 14 (28.0%)
7 
(14.0%)
8 
(15.4%)
14 
(26.9%)
15 
(28.8%)
8 
(15.4%)
 3 19 (38.0%)
6 
(12.0%)
15 
(28.8%)
11 
(21.2%0
16 
(30.8%0
9 
(17.3%)
ER status
 Negative 14 (26.4%)
5 
(9.4%)
0.990
11 
(19.3%)
10 
(17.5%)
0.707
15 
(27.3%)
6 
(10.9%)
0.606
 Positive 25 (47.2%)
9 
(17.0%)
17 
(29.8%)
19 
(33.3%)
22 
(40.0%)
12 
(21.8%)
PgR status
 Negative 19 (35.8%)
7 
(13.2%)
0.934
16 
(28.1%)
12 
(21.1%)
0.234
20 
(36.4%)
8 
(14.5%)
0.504
 Positive 20 (37.7%)
7 
(13.2%)
12 
(21.1%)
17 
(29.8%)
17 
(30.9%)
10 
(18.2%)
HER2 status
 Negative 37(71.2%) 14 (26.9%)
0.288*
29 
(52.7%)
25 
(45.5%)
0.473*
37 
(68.5%)
16 
(29.6%)
0.315*
 Positive 0 (0.0%) 1 (1.9%) 0 (0.0%) 1 (1.8%) 0 (0.0%) 1 (1.9%)
(Continued )
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having a significantly worse breast cancer-specific survival 
(P=1x10-5) in this cohort.
In the core biopsies, high calpastatin expression 
was significantly associated with adverse breast cancer-
specific survival (P=0.035) in the non-inflammatory breast 
cancer cases (Figure 2C), whereas low calpastatin was 
significantly associated with adverse survival (P=0.020) 
in the inflammatory breast cancer cases (Figure 2A). Low 
calpain-1 expression was associated with adverse survival 
in inflammatory breast cancer cases (P=0.003) (Figure 2B) 
and low calpain-2 was associated with adverse survival 
in the non-inflammatory breast cancer cases (P=0.031) 
(Figure 2D).
In the surgically excised cases, expression of 
calpastatin, calpain-1 and calpain-2 was not associated 
with breast cancer specific survival in the total patient 
cohort (P=0.347, P=0.428, and P=0.220 respectively); 
no association with survival of the inflammatory or non-
inflammatory subgroups was observed.
The association between protein expression and 
patient survival in the inflammatory and non-inflammatory 
subgroups was explored further. All traditional prognostic 
variables were individually tested for their association 
with survival in the inflammatory and non-inflammatory 
patient subgroups using the Kaplan-Meier method with 
significance determined using the log-rank test. In the 
inflammatory subgroup none of the traditional prognostic 
variables were associated with patient survival including 
patient age, histological grade, tumour size, lymph 
node status and ER, PgR or HER2 receptor status (with 
individual Kaplan-Meier statistics of P=0.450, P=0.188, 
P=0.709, P=0.239, P=0.814, P=0.194 and P=0.953 
respectively). Multivariate Cox regression was performed 
using these potential confounding factors, despite them 
not individually being associated with survival; calpastatin 
expression remained significantly associated with the 
survival of patients with inflammatory disease (Hazard 
ratio (HR)= 0.36, 95% confidence interval (CI)= 0.001-
0.896, P=0.043) (Table 3). Calpain-1 expression was not 
independently associated with survival when potential 
confounding factors were included in the analysis.
In the non-inflammatory patient subgroup none of 
the traditional prognostic variables were associated with 
patient survival including patient age, histological grade, 
tumour size, lymph node status and ER, PgR or HER2 
receptor status (with individual Kaplan-Meier statistics of 
P=0.429, P=0.935, P=0.244, P=0.648, P=0.568, P=0.141 
and P=0.892 respectively). Multivariate Cox regression 
was performed using these potential confounding factors, 
despite them not being individually associated with 
survival; neither calpastatin nor calpain-2 expression were 
independently associated with survival in this analysis.
DISCUSSION
The expression of calpain-1, calpain-2 and 
calpastatin was determined in diagnostic core biopsy 
samples taken from patients with large but operable breast 
cancer or locally advanced breast cancer who subsequently 
received neoadjuvant chemotherapy prior to surgical 
resection. In addition, matched samples from surgically 
excised specimens were available and were also assessed 
for calpain-1, calpain-2 and calpastatin expression. This 
study demonstrates that high calpastatin expression in 
the diagnostic core biopsy was significantly associated 
with improved survival in patients with inflammatory 
breast cancer, while the reverse was observed in non-
inflammatory cases. In addition, low calpain-2 expression 
was associated with adverse survival in non-inflammatory 
breast cancer patients and low calpain-1 expression was 
associated with adverse survival in inflammatory breast 
cancer patients.
The calpain system has previously been shown to 
be associated with the prognosis of breast cancer patients 
with early invasive disease, when determined on surgically 
excised specimens prior to adjuvant treatments. Studies 
have shown that high calpain-2 expression is associated 
with adverse breast cancer-specific survival in basal-like 
and triple-negative phenotype breast cancers [6], high 
calpain-1 expression and adverse relapse free survival in 
HER2 positive breast cancer patients treated with adjuvant 
chemotherapy and trastuzumab and high calpastatin 
expression with the absence of lymphovascular invasion 
determined by immunohistochemistry [7, 8]. However, 
in the current study we have shown in large but operable 
breast cancer, where expression of the calpain system was 
Calpastatin Calpain-1 Calpain-2
Low High P value Low High P value Low High P value
Size
 less than 2cm 14 (30.4%)
1 
(2.2%)
0.070*
11 
(22.9%)
6 
(12.5%)
0.278
10 
(21.3%)
6 
(12.8%)
0.555
 2cm or greater 20 (43.5%)
11 
(23.9%)
15 
(31.3%)
16 
(33.3%)
22 
(46.8%)
9 
(19.1%)
The P values are resultant from Pearson χ2 test of association or Fishers Exact when an asterisk is included. Significant 
P values are indicated in bold. ER is oestrogen receptor and PgR is progesterone receptor.
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determined in core biopsies taken prior to neoadjuvant 
chemotherapy and in tissue from surgical resection, 
that high calpastatin expression and high calpain-1 is 
significantly associated with improved breast cancer-
specific survival in patients with inflammatory cancer 
and that low calpastatin or high calpain-2 expression is 
significantly associated with improved breast cancer-
specific survival in patients with non-inflammatory 
cancer. Such results suggest that the calpain system plays 
differing roles in different steps of tumour progression 
and in response to therapy pre- and post- tumour 
excision. Perhaps the most interesting observation is 
that of calpastatin expression, whereby high expression 
is associated with improved survival of inflammatory 
breast cancer and high expression is associated with 
adverse survival of non-inflammatory breast cancer. This 
observation suggests that the role that calpastatin plays in 
these two breast cancer types is distinct and important.
The calpain system has been shown to function 
in numerous cellular functions, including cytoskeletal 
remodelling, cell signalling, survival and apoptosis, and 
we have previously hypothesised that these paradoxical 
functions depend upon the context of calpain activation. In 
this study, we have measured calpain system expression, 
rather than resultant calpain activity in core biopsy samples 
from patients subsequently treated with neoadjuvant 
chemotherapy and surgical resection. As calpain activity 
is closely linked to apoptosis, it may be that calpain 
activity is important in tumours that will be treated with 
neoadjuvant chemotherapy. The reverse may be true 
when early invasive tumours are surgically resected and 
patients treated with various different therapies, including 
radiotherapy and adjuvant chemotherapy. We cannot 
predict the levels of calpain activity from the expression 
of the calpain system, as various factors are involved with 
the activation of the protease. It would be of interest to 
determine calpain activity, which may be possible using 
antibodies against the products of calpain proteolysis; 
however such reagents would require validation to 
determine their use in malignant tissue [18, 19].
Calpain and calpastatin have been shown to be 
linked with the process of lymphovascular invasion 
in previous tissue based and in-vitro studies [8, 20]. In 
this study, no association was observed between calpain 
or calpastatin expression and lymphovascular invasion 
determined in the surgically resected sample, which may 
Figure 2: Kaplan-Meier analysis of breast cancer specific survival showing the impact of high (black line) and low 
(grey line) calpastatin A. and calpain-1 B. in patients with inflammatory breast cancer and calpastatin C. and calpain-2 D. expression 
in patients with non-inflammatory breast cancer in the core biopsy samples. Significance was determined using the log-rank test and the 
numbers shown below the Kaplan-Meier survival curves are the number of patients at risk at 0, 40, 80 and 120 months.
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be due to determination being made on haematoxylin and 
eosin stained specimens over those stained with antibodies 
against lymphatic or blood endothelial cell specific 
markers. Inflammatory breast cancer can be associated 
with exaggerated frequencies of lymphovascular invasion 
and lymph node involvement [21], however in the 
inflammatory subset, no association was observed between 
lymphovascular invasion and the expression of calpain 
or calpastatin. There was also no association between 
lymphovascular invasion and inflammatory disease 
(χ2=1.939, d.f.=1, P=0.164); the presence of inflammatory 
disease was significantly associated with survival of 
patients (P=1.0x10-5) as was lymphovascular invasion 
(P=0.004). These patients have all been treated with up to 
eight cycles of neoadjuvant chemotherapy which is likely 
to have affected these findings.
This study has demonstrated that low expression of 
calpain-2 and high expression of calpastatin determined 
in diagnostic core biopsy samples is significantly 
associated with adverse breast cancer-specific survival 
in non-inflammatory large but operable primary breast 
cancer. Furthermore, low expression of calpastatin and 
calpain-1 is significantly associated with adverse breast 
cancer-specific survival in inflammatory large but operable 
primary breast cancer. In addition to the association with 
survival of these patients, high calpastatin expression is 
associated with ER positive tumours and high calpain-1 
expression is associated with PgR positive tumours.
These findings may have important implications 
when investigating calpain and calpastatin expression 
in breast cancer as this data suggests that the presence 
of calpain, presumably active calpain, is beneficial for 
tumours treated with chemotherapy prior to surgery and 
that the traditional view that calpain activity in breast 
cancer is clearly associated with adverse patient prognosis 
may be setting dependent. Importantly this may suggest 
that future calpain inhibition strategies as a method of 
therapeutic intervention in breast cancer may require 
important treatment caveats imposed dependent upon the 
patient group and planned treatment regimen.
In conclusion, low calpain-2 and high calpastatin 
expression are associated with adverse breast cancer-
specific survival in non-inflammatory large but operable 
breast cancer treated with neoadjuvant chemotherapy, 
and determining the expression of these important 
proteins may be of clinical relevance. Furthermore, low 
calpain-1 and calpastatin expression are associated with 
adverse survival of patients with inflammatory large but 
operable breast cancer. As part of future research, these 
results require validation in multi-centre cohorts of locally 
advanced breast cancer patients treated with neoadjuvant 
chemotherapy.
MATERIALS AND METHODS
Clinical samples
This study is reported in accordance with REMARK 
criteria. Ethical approval was granted under the title 
‘Studies of the biological significance of breast cancer 
subtype’ (Leeds (East) REC no: 06/Q1206/180). This 
study utilised 143 4μm thick whole mount sections of 
formalin fixed paraffin embedded (FFPE) core biopsy 
specimens and 4μm sections of a tissue microarray of 
surgically excised FFPE specimens from 68 matched 
patients. Comprehensive clinical data, including 
chemotherapy regimen, type of surgery and imaging 
characteristics (mammography and MRI) were collected.
Patients were treated at the Leeds Teaching 
Hospitals NHS Trust in the period between 2005 and 2009 
and had long term follow-up information available. The 
median survival time was 100 months; the median follow-
up of patients alive (n=76) was 49 months (range 1-107) as 
calculated by the reverse Kaplan-Meier method. Patients 
included in this study were those with inflammatory or 
non-inflammatory breast cancer where primary surgery 
Table 3: Cox proportional hazards analysis for overall survival for calpastatin expression in breast cancer patients 
with large but operable inflammatory disease
P value Exp(B)
95.0% CI for Exp(B)
Lower Upper
Calpastatin 0.043 0.036 0.001 0.896
Tumour grade 0.125 0.046 0.001 2.351
tumour size 0.549 3.142 0.074 132.603
Patient age 0.480 0.285 0.009 9.329
ER status 0.292 0.013 0.000 40.877
PgR status 0.267 20.462 0.099 4232.348
HER2 status 0.376 1.712 0.521 5.626
Exp (B) is used to denote hazard ratio and 95% CI is used to denote 95% confidence interval.
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was one of the options considered; but due to the 
anatomical, pathological or molecular characteristics of 
the tumour, the patient would also be an obligate candidate 
for cytotoxic chemotherapy. The decision was made with 
the patient to use chemotherapy as the primary treatment 
(neo-adjuvant chemotherapy) so that chemotherapy 
drugs could be tailored to response, and with the hope 
that following response to chemotherapy surgery may be 
less radical. For patients who failed to respond, or those 
patients with residual invasive disease (no response/
partial pathological response), slides were reviewed and 
a representative block was selected and marked for tissue 
microarray construction as per the published guidance 
[22].
Initial treatment was anthracycline based 
chemotherapy and response was monitored by serial MRI 
scanning at baseline and repeated after every two cycles 
of treatment according to standard practice; chemotherapy 
was switched to docetaxel at the point when the response 
was considered inadequate. The modified response criteria 
was as follows; complete response was the complete 
radiological absence of previously documented lesions; 
almost complete response was the complete radiological 
absence of all previously documented lesions and a blush 
of residual enhancement; partial response was a greater 
than 50% reduction in diameter of the of the main tumour 
bulk or 25-50% reduction in the diameter of the main 
tumour bulk and improved enhancement curve; minimal 
response was 25-50% reduction in main tumour bulk and 
no improvement in enhancement curve; stable response 
was no change to appearance of tumour and progression 
was defined as progressive lesions or 25% increase in 
tumour bulk. Trastuzumab was introduced in patients who 
were HER2 positive at the time of switch to docetaxel 
chemotherapy. All patients received between 6 and 8 
cycles of chemotherapy which was followed by surgical 
treatment of residual disease, the extent of surgery being 
determined by MRI scanning and multi-disciplinary team 
discussion. Following surgical excision patients received 
adjuvant endocrine therapy, trastuzumab, and radiotherapy 
according to standard practice.
The median age of the patients was 48 years 
(ranging from 23-83 years), 49.5% of cases were lymph 
node negative (46/93), 68.6% of patients had non-
inflammatory disease (94/137), 30.4% of patients had 
inflammatory disease (43/137) and 52.5% of patients 
had grade III disease at the time of core biopsy (61/118); 
where patient number does not total 143 information 
was not available for the remaining patients. Detailed 
clinicopathological data was recorded at the time of core 
biopsy and is shown in Table 1. Patients were assessed 
and managed in a standardised manner according to their 
clinical history and tumour characteristics. Breast cancer-
specific survival was defined as the time from diagnosis 
to death from breast cancer. Histopathological features 
were reported as complete pathological response, where 
no residual invasive tumour was observed; partial 
response, where evidence of response to therapy was 
observed; and no/minimal evidence of response to 
therapy [23].
Immunohistochemistry
Tissue microarray construction has been 
described previously [24]. Slides were deparaffinised 
in xylene, followed by rehydration in ethanol and 
water. Antigen retrieval was performed in 0.01mol L-1 
sodium citrate buffer (pH6.0) in a microwave for 20 
minutes, with 10 minutes at 750W and 10 minutes at 
450W. Immunohistochemistry was performed using 
a Novolink Polymer Detection kit (Leica) according 
to the manufacturers’ instructions. Briefly, Peroxidase 
Block solution was added to tissues following antigen 
retrieval, and tissue was then washed with Tris-buffered 
saline before incubation with Protein Block solution. 
Primary antibodies against calpain-1 (1:1000; Santa Cruz 
Biotechnology clone P-6), calpain-2 (1:2500; Chemicon 
rabbit polyclonal AB1625) and calpastatin (1:40000; 
Chemicon clone PI-11) were incubated on tissue for 
one hour at room temperature, with antibody specificity 
determined by Western blotting. Following antibody 
incubation, tissues were washed and subject to incubation 
with Post Primary solution, then washed and incubated 
with Novolink Polymer solution. Immunohistochemical 
reactions were developed using 3,3’ diaminobenzidine 
as the chromogenic substrate and sections were 
counterstained with haematoxylin. After staining, tissues 
were dehydrated and fixed in xylene prior to mounting 
with DPX (Sigma). Breast tumour composite sections 
comprised of grade 1 and 2 early stage invasive tumours 
were included as positive and negative controls, where in 
the negative control primary antibody was omitted during 
each staining run.
Assessment of staining was conducted at x200 
magnification using a Nikon Eclipse 80i microscope 
for core biopsy specimens, or following scanning 
the slides using a Nanozoomer Digital Pathology 
Scanner (Hamamatsu Photonics) for the TMA. 
Staining was assessed semi-quantitatively using an 
immunohistochemical H-score, where staining intensity 
was assessed as none (0), weak (1), medium (2), and 
strong (3) over the percentage area of each staining 
intensity. H-scores were calculated by multiplying the 
staining intensity by the staining area and resulted in H-
scores ranging from 0 to 300. Both core biopsy and the 
TMA of surgically excised specimens had greater than 
30% of the cases scored by two independent assessors, 
blinded to each other’s scores and the clinical outcome of 
the patients. The single measures intra-class correlation 
efficient was used to determine the level of concordance 
between scorers, which was above 0.7 for all markers 
assessed, indicating good concordance.
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Statistical analyses
Statistical analyses were performed using SPSS 22.0 
software and protein expression was dichotomised into 
high and low expression based on breast cancer-specific 
survival using X-tile software which allows for non-
biased cut point generation [25]. Relationships between 
categorised protein expression and clinicopathological 
variables were determined using Pearson Chi Square 
test of association (χ2) where there were more than two 
variables, or Fishers Exact test in a 2×2 table when a cell 
count less than 5 was observed. Overall disease-specific 
survival curves were plotted according to the Kaplan-
Meier method with significance determined using the log-
rank test. Spearman rank order correlations were used to 
assess the correlation between protein-protein expression. 
All differences were deemed significant at the level of 
P<0.05.
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